<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Thioridazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00679</strong>&#160; (APRD00596)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00679/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00679/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00679.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00679.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00679.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00679.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00679.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00679">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Thioridazin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Thioridazine Hydrochloride</strong>
          <div class="cas">130-61-0</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000503/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000503/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: NZFNXWQNBYZDAQ-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 406.130417961</li>
              <li>Average Mass: 407.035</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000503">DBSALT000503</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aldazine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mallorol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Meleril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mellaril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mellerette</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Melleretten</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Melleril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Novoridazine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ridazin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ridazine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sonapax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Thioril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li>
<li><a href="/mesh/dopamine-antagonists">Dopamine Antagonists</a></li>
<li><a href="/mesh/phenothiazines">Phenothiazines</a></li></ul></td></tr><tr><th>CAS number</th><td>50-52-2</td></tr><tr><th>Weight</th><td>Average: 370.575<br>Monoisotopic: 370.153740222</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>KLBQZWRITKRQQV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00679.gif?1265922772">show</a>(8.15 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiazines</td></tr><tr><th>Subclass</th><td>Phenothiazines</td></tr><tr><th>Direct parent</th><td>Phenothiazines</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Piperidines; Tertiary Amines; Polyamines; Thioethers</td></tr><tr><th>Substituents</th><td>piperidine; benzene; tertiary amine; thioether; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of schizophrenia and generalized anxiety disorder.</td></tr><tr><th>Pharmacodynamics</th><td>Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.</td></tr><tr><th>Mechanism of action</th><td>Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.</td></tr><tr><th>Absorption</th><td>60%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>21-25 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9068</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9901</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7912</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7863</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7943</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7981</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5068</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.908</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7697</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8308</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5826</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8703
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9528
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5395 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.906
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8384
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li>
<li>Actavis mid atlantic llc</li>
<li>Alpharma us pharmaceuticals division</li>
<li>Hi tech pharmacal co inc</li>
<li>Pharmaceutical assoc inc div beach products</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Wockhardt eu operations (swiss) ag</li>
<li>Roxane laboratories inc</li>
<li>Ivax pharmaceuticals inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical inc</li>
<li>Superpharm corp</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>West ward pharmaceutical corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>Heartland Repack Services LLC</li>
<li>Interpharm Pharmaceutical Products Inc.</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li>Pharmaceutical Packaging Center</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td></td></tr><tr><td>Suspension</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Thioridazine hcl powder</td><td>11.16USD</td><td>g</td></tr><tr><td>Thioridazine HCl 200 mg tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 150 mg tablet</td><td>1.01USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 100 mg tablet</td><td>0.69USD</td><td>tablet</td></tr><tr><td>Thioridazine 100 mg tablet</td><td>0.67USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 50 mg tablet</td><td>0.61USD</td><td>tablet</td></tr><tr><td>Thioridazine 50 mg tablet</td><td>0.58USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 25 mg tablet</td><td>0.49USD</td><td>tablet</td></tr><tr><td>Thioridazine 25 mg tablet</td><td>0.47USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 15 mg tablet</td><td>0.45USD</td><td>tablet</td></tr><tr><td>Thioridazine HCl 10 mg tablet</td><td>0.35USD</td><td>tablet</td></tr><tr><td>Thioridazine 10 mg tablet</td><td>0.33USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>73 &#176;C</td><td>PhysProp</td></tr><tr><td>boiling point</td><td>230 &#176;C at 2.00E-02 mm Hg</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>0.0336 mg/L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>5.90</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>pKa</td><td>9.5</td><td>EL TAYAR,N ET AL. (1985)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>8.55e-04 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.93</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.47</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5.6</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest basic)</td><td>8.93</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>6.48</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>113.52</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>43.26</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00373" target="_blank">D00373 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5452" target="_blank">5452 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46509070" target="_blank">46509070 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.5253.html" target="_blank">5253 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=9566" target="_blank">9566 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL479" target="_blank">CHEMBL479 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000476" target="_blank">DAP000476 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451666" target="_blank">PA451666 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=100" target="_blank">100 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=100" target="_blank">100 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=360244" target="_blank">360244 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/thioridazine.htm" target="_blank">http://www.rxlist.com/cgi/generic3/thioridazine.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/thioridazine.html" target="_blank">http://www.drugs.com/cdi/thioridazine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Thioridazine" target="_blank">Thioridazine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N05AC02<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N05#N05">N05 &#8212; PSYCHOLEPTICS</a></li><li><a href="/atc/N05A#N05A">N05A &#8212; ANTIPSYCHOTICS</a></li><li><a href="/atc/N05AC#N05AC">N05AC &#8212; Phenothiazines with piperidine structure</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00679.pdf?1265922739">show</a>(44.7 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Thioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy. </td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine</td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. </td></tr><tr><td><a href="/drugs/DB01053">Benzylpenicillin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01158">Bretylium</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Bupropion may increase the effect and toxicity of thioridazine.</td></tr><tr><td><a href="/drugs/DB00608">Chloroquine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Concurrent use with drugs that prolong QTc interval is contraindicated. </td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01075">Diphenhydramine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01195">Flecainide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Thioridazine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01218">Halofantrine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB04871">Lorcaserin</a></td><td>Avoid combination.The combination is likely to reduce the metabolism of Thioridazine.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01578">Metrizamide</a></td><td>Increased risk of convulsions</td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00738">Pentamidine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00830">Phenmetrazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00960">Pindolol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Increased risk of cardiotoxicity and arrhythmias.</td></tr><tr><td><a href="/drugs/DB00571">Propranolol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Possible additive effect on QT prolongation</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB06144">Sertindole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06145">Spiramycin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Ticlopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.  Avoid combination.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Concomitant use is contraindicated. </td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>